

---

**Optimization of the Tango™ EDG1-*bla* U2OS Cell Line**

---

**Tango™ EDG1-*bla* U2OS cells**

Catalog Numbers – K1520

**Cell Line Descriptions**

Tango™ EDG1-*bla* U2OS cells contain the human Endothelial Differentiation Gene 1 (EDG1) linked to a TEV protease site and a Gal4-VP16 transcription factor stably integrated into the Tango™ GPCR-*bla* U2OS parental cell line. This parental cell line stably expresses a beta-arrestin/TEV protease fusion protein and the beta-lactamase (*bla*) reporter gene under the control of a UAS response element.

Tango™ EDG1-*bla* U2OS cells have been functionally validated for Z' factor and EC<sub>50</sub> concentrations of Sphingosine-1-phosphate (Figure 1). In addition, Tango™ EDG1-*bla* U2OS cells have been tested for assay performance under variable conditions.

**Target Description**

S1P is a bioactive lysophospholipid with diverse biological functions. It is a key cell signaling molecule that has been shown to act as both an intracellular second messenger and an extracellular ligand for a related group of 5 GPCRs in the endothelial differentiation gene (EDG) family of receptors (1,2). S1P is a polar sphingolipid metabolite that is derived through the multi-step enzymatic metabolism of the abundant membrane phospholipid, sphingomyelin (3). S1P is found at high nM levels in human serum and plasma where it is bound extensively by albumin and other plasma proteins (3,4). Most of the S1P in the blood is released from activated platelets (5), while a small percentage of circulating S1P is released by other blood cells (6).

The S1P receptors were originally classified in the EDG family of receptors. The EDG family was later divided into two distinct groups of receptors based on their ligand specificity for either Lysophosphatidic acid (LPA) or S1P. There are three high affinity LPA receptors LPA<sub>1</sub>, LPA<sub>2</sub>, and LPA<sub>3</sub> (formally EDG2, EDG4, and EDG7), and five high affinity S1P receptors S1P<sub>1</sub>, S1P<sub>2</sub>, S1P<sub>3</sub>, S1P<sub>4</sub> and S1P<sub>5</sub> (formally EDG1, EDG5, EDG3, EDG6, and EDG8). S1P<sub>1-5</sub> are differentially linked via G<sub>i</sub>, G<sub>q</sub>, G<sub>12/13</sub>, and Rho to multiple effector systems and diverse biological functions (3).

## Validation Summary

Testing and validation of this assay was evaluated in a 384-well format using LiveBLazer™-FRET B/G Substrate.

### 1. Sphingosine-1-phosphate (S1P) dose response under optimized conditions

	<u>Dividing Cells</u>
EC <sub>50</sub>	4.7 nM
Z'-factor	0.66
Recommended cell no. /well	= 10,000
Recommended Stim. Time	= 5 hrs
Max. [Stimulation]	= 1,000 nM

### 2. Alternate agonist dose response


FTY720-P EC<sub>50</sub> = 1 nM

### 3. Antagonist dose response

VPC23019 IC<sub>50</sub> = 9 nM

## Primary Agonist Dose Response


Figure 1 — Tango™ EDG1-*bla* U2OS cells dose response to S1P under optimized conditions



Tango™ EDG1-*bla* U2OS cells (10,000 cells/well) were plated in a 384-well format and incubated for 44-48 hours. Cells were stimulated with a dilution series of S1P (Avanti Polar Lipids 860492P) in the presence of 0.1% DMSO for 5 hours. Cells were then loaded with LiveBLazer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the response ratio plotted for each replicate against the concentrations of S1P.

## Alternate Agonist Dose Response and Selectivity


Figure 2 — Tango™ EDG1-*bla* U2OS cells dose response to FTY720-P



Tango™ EDG1-*bla* U2OS cells (10,000 cells/well) were plated in a 384-well format and incubated for 48 hours prior to stimulation with FTY720-P (Toronto Research Chemicals F805005) or S1P over the indicated concentration range in the presence of 0.1% DMSO for 5 hours. Cells were then loaded with LiveBLazer™-FRET B/G Substrate for 2 hours. Emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the response plotted against the indicated concentrations of agonist.

### Antagonist Dose Response


Figure 3 — Tango™ EDG1-*bla* U2OS cells dose response to VPC23019



Tango™ EDG1-*bla* U2OS cells (10,000 cells/well) were plated in a 384-well format and incubated for 44-48 hours. Cells were exposed to VPC23019 (Avanti Polar Lipids 857360) for 30 min. and then stimulated with an EC80 concentration of S1P (Avanti Polar Lipids 860492P) in the presence of 0.1% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm for the various substrate loading times were obtained using a standard fluorescence plate reader and the response plotted against the indicated concentrations of VPC23019.

### Assay Performance with Variable Serum Starvation Time

Figure 4 — Tango™ EDG1-*bla* U2OS cells dose response to S1P with 24 or 48 hour serum starvation times



Tango™ EDG1-*bla* U2OS cells (10,000 cells/well) were plated in a 384-well assay plate and incubated 24 or 48 hours. Cells were stimulated with a dilution series of S1P (Avanti Polar Lipids 860492P) in the presence of 0.1% DMSO for 5 hours. The cells were then loaded for 2 hours with LiveBLAzer™-FRET B/G Substrate. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and the response plotted against the indicated concentrations of S1P.

**References**

- 1) Van Brocklyn, J., Lee, M., Menzeleev, R., Olivera, A., Edsall, L., Cuvillier, O., Thomas, D., Coopman, P., Thangada, S., Liu, C., Hla, T., and Spiegel, S. (1998) *Journal of Cell Biology* **142**, 229-240
- 2) Stunff, H., Mikami, A., Giussani, P., Hobson, J., Jolly, P., Milstien, S., and Spiegel, S. (2004) *J Biol Chem* **279**, 34290-34297
- 3) Pyne, S., Pyne, N.J. (2000) *Biochem. J.* **349**, 385-402
- 4) Rosen, H., Goetzl, E. (2005) *Nature Reviews Immunology* **5**, 560-570
- 5) Yatomi, Y., Ruan, F., Hakomori, S., and Igarashi, Y. (1995) *Blood* **86**, 193-202
- 6) Yang, L., Yatomi, Y., Miura, Y., Satoh, K., and Ozaki, Y. (1999) *Br J Haematol* **107**, 282-93